ライフサイエンスコーパス: bronchial asthma

1 FM) was evaluated in pediatric patients with bronchial asthma.

2 noted in management of atopic dermatitis and bronchial asthma.

3 mask in two young children with acute severe bronchial asthma.

4 les are considered as an emerging target for bronchial asthma.

5 n and pathology in allergic diseases such as bronchial asthma.

6 valuate the efficacy of omalizumab in severe bronchial asthma.

7 ls had sensorineural deafness, and three had bronchial asthma.

8 lizumab, was studied in patients with severe bronchial asthma.

9 modality for treating allergic reactions and bronchial asthma.

10 ey may play a significant pathogenic role in bronchial asthma.

11 gy in chronic inflammatory diseases, such as bronchial asthma.

12 nosed pulmonary sarcoidosis complicated with bronchial asthma.

13 in human patients with allergic rhinitis and bronchial asthma.

14 ategy for finding more efficient therapy for bronchial asthma.

15 the role of ASM in T(H) 2-regulated allergic bronchial asthma.

16 e., atherosclerosis, pulmonary fibrosis, and bronchial asthma.

17 ences associated with RSV infection, such as bronchial asthma.

18 cellular matrix proteins is a key feature in bronchial asthma.

19 ment and/or cure of allergic inflammation in bronchial asthma.

20 licated as a mediator of disease, especially bronchial asthma.

21 the inflammatory and neurogenic elements of bronchial asthma.

22 om human patients with allergic rhinitis and bronchial asthma.

23 ed diseases, such as allograft rejection, or bronchial asthma.

24 myocardial infarction, atherosclerosis, and bronchial asthma.

25 ne E4(LTE4)-are important mediators of human bronchial asthma.

26 steroid action in allergic diseases such as bronchial asthma.

27 l processes, may be an important mediator of bronchial asthma.

28 in the inflammatory response associated with bronchial asthma.

29 ffect of azelastine in patients with chronic bronchial asthma.

30 l to allergic inflammation and implicated in bronchial asthma.

31 ukotrienes implicated in the pathobiology of bronchial asthma.

32 les are considered as an emerging target for bronchial asthma.

33 ncluding lupus erythematosus, psoriasis, and bronchial asthma.

34 ciated with chronic rhinosinusitis (CRS) and bronchial asthma.

35 as being used to treat rheumatoid arthritis, bronchial asthma (6%), pemphigus (5%), or other processe

36 ds are used for a long time in patients with bronchial asthma, a decrease in adrenal cortex function

37 ence in diverse allergic disorders including bronchial asthma, allergic rhinitis, and cutaneous conta

38 ctions (LPRs) are characteristic features of bronchial asthma, although the pathogenetic mechanisms r

39 ed in 99 allergic patients with intermittent bronchial asthma and 26 healthy donors.

40 ys important roles in the pathophysiology of bronchial asthma and allergic disorders; however, this c

41 reasons: First, the patient had a history of bronchial asthma and allergic rhinitis without any histo

42 nflammatory diseases in humans, particularly bronchial asthma and allergic rhinitis.

43 airway remodeling are consistent features of bronchial asthma and are correlated with disease chronic

44 s of chronic inflammatory disorders, such as bronchial asthma and atherosclerosis.

45 Diagnosis of bronchial asthma and atopic dermatitis was made, but she

46 yl leukotrienes are established mediators of bronchial asthma and have agonist roles analogous to tho

47 g coeliac disease, diabetes mellitus type 1, bronchial asthma and inflammatory bowel diseases.

48 led corticosteroids in patients with chronic bronchial asthma and not lead to a deterioration in pulm

49 tor blockers are effective in treating human bronchial asthma and the mouse is often used to model hu

50 e has been suffering from atopic dermatitis, bronchial asthma, and food allergies since childhood.

51 athophysiology of allergic diseases, such as bronchial asthma, and in host immunity to certain organi

52 athophysiology of allergic diseases, such as bronchial asthma, and in host immunity to parasitic orga

53 ay hyperreactivity (AHR) is a key feature of bronchial asthma, and inhalation of irritants may facili

54 Atopic dermatitis and bronchial asthma are common diseases in children.

55 The diagnosis was bronchial asthma associated with bronchiolitis.

56 A 49-year-old man who developed bronchial asthma at age 48 was diagnosed with EGPA in ou

57 ons in the pathogenesis of diseases, such as bronchial asthma, atherosclerosis, and pulmonary fibrosi

58 Concomitant bronchial asthma, atopic dermatitis, and food allergies

59 gical disorders including allergic rhinitis, bronchial asthma, atopic dermatitis, food allergies, urt

60 w reports on the effects of immunotherapy on bronchial asthma (BA) and allergic rhinitis (AR) in Japa

61 Evidences have shown that bronchial asthma (BA) enhances the risk of pulmonary thr

62 y, the prevalence of allergic rhinitis among bronchial asthma (BA) patients was reported to be 67.3%

63 was initially developed for the treatment of bronchial asthma but which also has been used for cerebr

64 is, ulcerative colitis, Crohn's disease, and bronchial asthma, but the mechanism is poorly understood

65 In intractable bronchial asthma cases, it is necessary to consider the

66 We suspected bronchial asthma complicated by IgG4-related disease due

67 When dupilumab was initiated for bronchial asthma complicated by IgG4-related disease, th

68 dermatitis, diagnosed at 1 year of age, and bronchial asthma, diagnosed at 4 years of age.

69 In bronchial asthma, eosinophils (EOS) adhere to, and migra

70 Any mother with a child diagnosed with bronchial asthma for more than 3 months, and who attende

71 ic rhinitis/rhinoconjunctivitis with/without bronchial asthma (Global Initiative for Asthma I/II) rec

72 The role of human basophils in bronchial asthma has been hard to define.

73 otential in adults with airway reactivity or bronchial asthma has been reported, data are lacking on

74 0% of diseases that include angina pectoris, bronchial asthma, herpes simplex, and duodenal ulcer.

75 Its use in the management of pediatric bronchial asthma, however, is currently not approved in

76 cious for bronchoconstriction in humans with bronchial asthma; however, the clinical response to thes

77 V) infection is considered a risk factor for bronchial asthma; however, the synergy between allergen

78 xidative stress have both been implicated in bronchial asthma; however, there is no previous study th

79 s (LAMA) are used for long-term treatment of bronchial asthma in adults.

80 All patients had a diagnosis of bronchial asthma inadequately controlled by at least a m

81 ed in different chronic disorders, including bronchial asthma, inflammatory bowel diseases, and skin

82 Bronchial asthma is a chronic inflammatory disease with

83 Differentiation from bronchial asthma is also important.

84 Bronchial asthma is associated with an inflammatory proc

85 r type 1 (Th1) mediated immune response, and bronchial asthma is characteristic of the Th2.

86 Bronchial asthma is characterized by episodic airway obs

87 f hypercitrullination in the pathogenesis of bronchial asthma is still unknown.

88 The merger rate of bronchial asthma of the patients seen in pediatrics/inte

89 oids, first-line treatment for patients with bronchial asthma, on mucosal tolerance remain unknown.

90 nagement strategies by patients experiencing bronchial asthma or atopic dermatitis in SSA.

91 in children, particularly in cases of severe bronchial asthma or those without atopic disease that ar

92 western part of Yokohama City managed adult bronchial asthma patients via a coordinated care system

93 However, severe bronchial asthma persisted, with some patients having un

94 Since uncontrolled severe-persistent bronchial asthma results in repeated hospitalization and

95 ase of a 17-year-old woman with a history of bronchial asthma since two years of age.

96 However, many features of bronchial asthma, such as smooth muscle contraction, muc

97 ing lung function in patients suffering from bronchial asthma, the most common chronic inflammatory l

98 Bronchial asthma, the most prevalent cause of significan

99 Although he was treated for bronchial asthma, the symptom did not improve.

100 he tricyclic antidepressant amitriptyline in bronchial asthma, there is emerging evidence that inhale

101 the blood of adult and elderly patients with bronchial asthma to establish potential association of C

102 by controversial results in mouse models of bronchial asthma treated with anti-IL-5 Ab and the failu

103 ine, plays a pivotal role in pathogenesis of bronchial asthma via IL-13 receptor alpha1 (IL-13Ralpha1

104 idered to reflect VCD, and the treatment for bronchial asthma was stepped down without any recurrence

105 Hereby, Asm(-/-) animals are protected from bronchial asthma, which possibly offers novel therapeuti

106 , the treatment of inhaled steroid-resistant bronchial asthma with dupilumab can also improve IgG4-re

107 ients were women, and were diagnosed to have bronchial asthma with the reversibility of airway contra

108 We clinically diagnosed the patient with bronchial asthma, with an increase in peripheral blood e

109 adult-onset atopic (Aspergillus-sensitized) bronchial asthma without allergic bronchopulmonary asper